These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37910303)

  • 1. Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE.
    Lipton RB; Contreras-De Lama J; Serrano D; Engstrom E; Ayasse ND; Poh W; Cadiou F; Manack Adams A
    Neurol Ther; 2024 Feb; 13(1):69-83. PubMed ID: 37910303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
    Manack Adams A; Hutchinson S; Engstrom E; Ayasse ND; Serrano D; Davis L; Sommer K; Contreras-De Lama J; Lipton RB
    J Headache Pain; 2023 Aug; 24(1):102. PubMed ID: 37537578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubrogepant to treat migraine.
    Dhir A
    Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 7. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubrogepant in the Acute Management of Migraine: A Narrative Review.
    Chiang CC; VanderPluym JH
    J Pain Res; 2021; 14():1185-1192. PubMed ID: 33948091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
    Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
    Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials.
    Lipton RB; Singh RBH; Revicki DA; Zhao S; Shewale AR; Lateiner JE; Dodick DW
    J Headache Pain; 2022 Apr; 23(1):50. PubMed ID: 35468729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
    MacGregor EA; Hutchinson S; Lai H; Dabruzzo B; Yu SY; Trugman JM; Ailani J
    Headache; 2023 Sep; 63(8):1135-1144. PubMed ID: 37655536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.
    Moore E; Fraley ME; Bell IM; Burgey CS; White RB; Li CC; Regan CP; Danziger A; Stranieri Michener M; Hostetler E; Banerjee P; Salvatore C
    J Pharmacol Exp Ther; 2020 Jan; ():. PubMed ID: 31992609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
    Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
    Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
    Nedd M; Garland S; Falk N; Wilk A
    Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States.
    Varnado OJ; Gulati T; Wheeler A; Hoyt M
    Patient Prefer Adherence; 2023; 17():3449-3459. PubMed ID: 38143945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
    Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
    Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.